US patents issued to Akaal Pharma on S1P1 receptor modulators useful for the treatment of autoimmune and inflammatory diseases

Several similar patent applications have been filed in Canada, Europe, Japan, China and India.

The patents cover Akaal Pharma’s internally discovered various classes of novel compounds (small molecule drug candidates) as modulators of Sphingosine 1-Phosphate receptors (S1P) useful in the treatment of autoimmune and inflammatory diseases. Novel chemical scaffolds, synthetic intermediates and processes for the manufacture of drug candidates are claimed in these issued composition-of-matter patents. Several similar patent applications have been filed in Canada, Europe, Japan, China and India. Nearly 50 million people are afflicted with various autoimmune and inflammatory diseases in the US alone.

“These issued patents strengthen our patent position and expand further the intellectual property discovered internally by Akaal Pharma’s medicinal chemistry and drug discovery team. We believe that novel small molecules claimed in these patents could provide new generation of safer and more effective small molecule drugs for the treatment of autoimmune and inflammatory diseases including psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis, Crohn’s disease, stroke and others.” said Dale Dhanoa, CEO of Akaal Pharma.